VolitionRx (VNRX) said Thursday it has extended its Nu.Q Vet Cancer Test supply deal with Fujifilm Vet Systems in Japan for a new five-year initial term to include the chemiluminescent immunoassay version of the test through an automated analyzer platform.
The agreement previously allowed Fujifilm to provide the test to Japanese veterinarians in a manual format, VolitionRx said.
Fujifilm will work with VolitionRx for the final validation and verification of the automated platform for canine cancer screening for a launch in the summer, according to VolitionRx.